N 1 3 2002

6-14-

TECH CENTER 1600/2900

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:Assistant Commissioner for PatentsWashington, D.C. 20231 on

May 23, 2000 Werd (Arto

Attorney Docket No.: 20093A-002100US

OIPE DO S TOOK OF TRADERINANTE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gerald P. Murphy et al.

Examiner:

M. Schmidt

Application No.: 09/301,380

Filed: June 15, 2001

Art Unit:

1635

For: NR-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC

USES FOR TUMORS

AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed November 23, 2001, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please carry out the following amendments to the specification. An Appendix showing all changes to the designated portions of the specification is attached to this amendment as required by 37 CFR § 1.121(b).

Please delete the pages designated "-i-" through "-v-" comprising the Table of Contents.

At page 4 please delete the paragraph beginning at line 22 and replace with the following:

Several CAM family members are implicated in the process of tumorigenesis including, *N-CAM*, CEA, (Carcinoembryonic Antigen), DCC (Deleted in Colon Carcinoma) and L1.

AI